Jeff Vinet
Ophthalmology · New Orleans, LANPI 1982091054
Payments from drug & device makers
Across 144 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$647
- Glaukos Corporation$588
- Bausch & Lomb, A Division Of Bausch Health US, LLC$254
- Dompe US, Inc.$246
- Ivantis, Inc$224
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 42 | $1,167 |
| AbbVie(2 entities) | 28 | $647 |
| Glaukos Corporation | 9 | $588 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $254 |
| Dompe US, Inc. | 5 | $246 |
| Ivantis, Inc | 2 | $224 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $221 |
| Bausch & Lomb Americas Inc. | 8 | $200 |
| Aerie Pharmaceuticals, Inc. | 9 | $184 |
| Novartis | 4 | $164 |
| Sun Pharmaceutical Industries Inc. | 2 | $136 |
| Genentech USA, Inc. | 1 | $133 |
| Oyster Point Pharma, Inc. | 4 | $108 |
| Mallinckrodt Hospital Products Inc. | 3 | $76 |
| Biotissue Holdings Inc. | 4 | $68 |
| Harrow Eye, LLC | 2 | $46 |
| NEW World Medical,inc. | 1 | $39 |
| Sight Sciences, Inc. | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 2 | $23 |
| Thea Pharma Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,585 in reported general payments places this provider in the 70th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 84 | $31,290 |
| RestasisCyclosporine | 34 | $29,374 |
| XiidraLifitegrast | 36 | $29,298 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $10,405 |
| Restasis MultidoseCyclosporine | 19 | $9,921 |
| ProlensaBromfenac Sodium | 21 | $7,419 |
| Prednisolone Acetate | 227 | $7,213 |
| VyzultaLatanoprostene Bunod | 14 | $6,455 |
| LumiganBimatoprost | 13 | $5,212 |
| Ketorolac Tromethamine | 87 | $2,360 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,359 |
| Bromfenac Sodium | 14 | $2,220 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 12 | $2,110 |
| Ciprofloxacin Hcl | 176 | $2,083 |
| Latanoprost | 280 | $1,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Lumigan, Combigan | $647 | $46,86677 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $200 | $35,75350 claims |
| NovartisIlevro | $164 | $31,29084 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $184 | $10,40522 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $254 | $7,41921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in New Orleans
- Delmar CaldwellNew Orleans$282K
- Ze ZhangNew Orleans$103K
- Rebecca MetzingerNew Orleans$63K
- Peter KastlNew Orleans$32K
- Benjamin LeeNew Orleans$7K
- Glen CangelosiNew Orleans$6K
- Matthew BoltonNew Orleans$5K
- Blake WilliamsonBaton Rouge$482K
- William ReadMonroe$303K
- Ruben GrigorianWest Monroe$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.